Boehringer Ingelheim’s Structured Venture into Biotech
By Sally Mardikian PhD
Pharma Deals Review: Vol 2008 Issue 97 (Table of Contents)
Published: 17 Jun-2008
DOI: 10.3833/pdr.v2008.i97.167 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Boehringer Ingelheim’s acquisition of US biotech Actimis, for the one aim of gaining rights to a small molecule asthma treatment, implements an unusual deal structure heavily dependent on the achievement of certain milestones...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS